OPALE, the Organization
for Partnerships in Leukemia
The OPALE Carnot institute is a healthcare industry’s preferred partner for the research and development of innovative solutions aimed at diagnosis, treatment and follow-up of patients in the field of leukemia and related diseases, the deadliest blood cancer and first child cancer.
An unparalleled partnership offer
The OPALE Carnot Institute gives healthcare companies unique access to the expertise of an internationally unparalleled consortium in the field of leukemia and related diseases. Our aim is to prolong or save the lives of more patients by accelerating therapeutic and diagnostic innovation across the entire research and development value chain.
Explore our offer
Carnot, a label of excellence
Granted by the French Ministry of Higher Education, Research and Innovation, the Carnot label is prestigious and highly selective.
Being labelled Carnot is a guarantee of scientific and operational excellence in R&D collaborations for our industrial partners.
The Carnot institutes follow their namesake Charter to guarantee top-tier collaborative research, effectively driving industrial advancements while ensuring ongoing scientific revitalization within the Carnot community.
"The OPALE Carnot Institute addresses many of the needs of manufacturers in the leukemia market, thanks to the specialization and depth of its R&D offering, accessible through a one-stop shop."
Medical Director of a pharmaceutical company
Member of OPALE's Strategic Advisory Committee
"Accelerating the emergence of innovative solutions for the diagnosis, treatment, and follow-up of patients in the field of leukemia and related diseases"
Pr Hervé Dombret
OPALE's Chairman
News
Les instituts Carnot au service du criblage de molécules thérapeutiques pour les leucémies
Feb. 27, 2025, 6:02 p.m.
La semaine dernière, les instituts Carnot OPALE, Chimie Balard Cirimat, I2C, CEA-Leti et IPGG Microfluidique se sont réunis pour la première fois pour capitaliser sur leur expertise scientifique et leur offre afin d'enrichir une activité de drug screening
> Read moreL’innovation au service de la lutte contre les leucémies : OPALE au PSCC Innovation Forum 2025
Feb. 21, 2025, 6:55 p.m.
l’Institut Carnot OPALE, The Organization for Partnerships in Leukemia, a participé au PSCC Innovation Forum 2025. Ce carrefour stratégique réunit startups, chercheurs et industriels pour collaborer et façonner l’avenir des traitements contre les leucémies.
> Read morePublication d'un article clé sur les conditions de libération des CAR-T cells fraîches sous exemption hospitalière
Feb. 21, 2025, 6:10 p.m.
Félicitations à Christophe Ferrand, Ibrahim Yakoub-Agha aux équipes de l'UNITC pour ce position paper, qui définit les conditions de production et libération des CAR-T cells fraîches dans le cadre de la réglementation hospitalière, facilitant une production académique accessible et standardisée.
> Read more